The Illinois-based global medical products and services
Baxter International Inc.
) announced a nationwide recall of CLINIMIX (Amino Acid in
Dextrose) and CLINIMIX E (Amino Acid with Electrolytes in
Dextrose with Calcium) injections due to the presence of a
harmful matter. These injections are used as a caloric component
and a protein source for parenteral nutrition.
ADVAXIS INC (ADXS): Get Free Report
BAXTER INTL (BAX): Free Stock Analysis Report
CELL THERAPEUT (CTIC): Get Free Report
HILL-ROM HLDGS (HRC): Free Stock Analysis
To read this article on Zacks.com click here.
If infused, the harmful matter in the product could lead to
blockages of blood vessels, resulting in stroke, heart attack, or
damage to other organs such as the kidney or liver. It could also
lead to allergic reactions, irritation, and inflammation in
tissues and organs. However, the company has not yet received any
reports of adverse events associated with the problem till date.
The product codes involved in the recall are 2B7729 (lot P287045,
exp 06/14), 2B7717 (lot P275883, exp 10/13) and 2B7709 (lot
P285122, exp 05/14). They were distributed to healthcare centers
and distributors in the U.S. between May 2012 and Oct 2013.
Recently, BAX announced that it has received U.S. Food and Drug
Administration (FDA) approval for its FEIBA (Anti-Inhibitor
Coagulant Complex) treatment as well as CE marking in Europe for
the VIVIA hemodialysis (HD) system.
FEIBA is the first and only FDA-approved treatment for routine
prophylaxis that controls the frequency of bleeding episodes in
hemophilia A or B patients, who have developed inhibitors.
Inhibitors are antibodies produced by the body's immune system in
response to factor replacement treatment. About one-third of
previously untreated patients with hemophilia A are at risk of
VIVIA hemodialysis system is capable of delivering frequent,
extended duration, short daily or nocturnal home HD therapy,
known as High Dose HD therapy1. It is designed with the patient
as the primary operator.
In November last year, Baxter entered a global licensing
Cell Therapeutics, Inc.
) to jointly develop and commercialize JAK2/FLT3 inhibitor
pacritinib that fights against genetic mutations linked to
myelofibrosis, leukemia and some tumors. As per the agreement,
BAX gained the commercialization rights for all indications for
pacritinib outside the U.S. while it jointly commercializes with
CTIC in the U.S.
Currently, BAX has a Zacks Rank #4 (Sell). Some better-ranked
medical product stocks include
Hill-Rom Holdings, Inc.
). Both of them carry a Zacks Rank #2 (Buy).